Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients: II. Treatment with connecting segment-1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation

Transplantation

Volumn 65, Issue 6, 1998, Pages 854-859

  Korom, Stephan ^a   Hancock, Wayne W ^b   Coito, Ana J ^a,c   Kupiec Weglinski, Jerzy W ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD3 ANTIGEN; COMPLEMENTARY DNA; FIBRONECTIN; GAMMA INTERFERON; INTEGRIN; INTERLEUKIN 12; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; GENETIC TRANSCRIPTION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN GRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ARTERIOSCLEROSIS; BINDING, COMPETITIVE; CHEMOKINE CCL2; CHRONIC DISEASE; FIBRONECTINS; GRAFT REJECTION; HEART TRANSPLANTATION; INFLAMMATION; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERFERON TYPE II; INTERLEUKIN-12; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RATS; RATS, INBRED BN; RATS, INBRED LEW; RECEPTORS, LYMPHOCYTE HOMING; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032571295     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199803270-00014     Document Type: Article

References (30)

1. Sanfilippo FP, Vaughn WK, Peters TG, et al. Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. JAMA 1992; 267: 247.
2. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection: an undefined conundrum. Transplantation 1991; 52: 389.
3. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney: have rational treatment options emerged? Transplantation 1992; 53: 1169.
4. Wasowska B, Wieder KJ, Hancock WW, et al. Cytokine and alloantibody networks in long-term cardiac allografts in rat recipients treated with rapamycin. J Immunol 1996; 156: 395.
5. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppresssive macrolides. Transplant Rev 1992; 6: 39.
6. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, Van De Water L. Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997; 150: 1757.
7. Coito AJ, Korom S, Graser E, Volk HD, Van De Water L, Kupiec-Weglinski JW. Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients: I. Treatment with connecting segment-1 peptides prevents acute rejection by suppressing intragraft mononuclear cell accumulation, endothelial activation, and cytokine expression. Transplantation 1998; 65: 699.
8. Wahl SM, Allen JB, Hines KL, et al. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994; 94: 655.
9. Molossi S, Elices M, Arrhenius T, Diaz R, Coluber C, Rabinovitch M. Blockade of very late antigen-4 integrin to fibronectin with connecting segment-1 peptides reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest 1995; 95: 2601.
10. Shimizu Y, Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J 1991; 5: 2292.
11. Hemler ME. VLA proteins in the integrin family: structure, functions, and their role on leukocytes. Annu Rev Immunol 1990; 8: 365.
12. McCarthy JB, Chelberg MK, Mickelson DJ, Furcht LT. Localization and chemical synthesis of fibronectin peptides with melanoma adhesion and heparin binding activities. Biochemistry 1988; 27: 1380.
13. Elices MJ, Tsai V, Strahl D, et al. Expression and functional significance in alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest 1994; 93: 405.
14. + cells in the sensitization and effector phases of accelerated graft rejection. Transplantation 1991; 51: 226.
15. Adams DH, Wyner LR, Karnovsky MJ. Experimental graft arteriosclerosis: II. Immunocytochemical analysis of lesion development. Transplantation 1993; 56: 794.
16. Hancock WW, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643.
17. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294.
18. Siegling A, Lehmann M, Platzer C, Emmrich F, Volk HD. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods 1994; 177: 23.
19. Steinhoff G, Behrend M, Richter N, et al. Distinct expression of cell-cell and cell-matrix adhesion molecules on endothelial cells in human heart and lung transplants. J Heart Lung Transplant 1994; 14: 1145.
20. Matsuyama T, Yamada A, Kay J, et al. Activation of CD4 cells by fibronectin and anti-CD3 antibody: a synergistic effect mediated by VLA-5 fibronectin receptor complex. J Exp Med 1989; 170: 1133.
21. Ostergaard HL, Ma EA. Fibronectin induces phosphorylation of a 120-kDa protein and synergizes with the T cell receptor to activate cytotoxic T cell clones. Eur J Immunol 1995; 25: 252.
22. Hynes RO. Fibronectins. New York: Springer, 1990.
23. + T cells and macrophages. Immunology 1993; 78: 50.
24. Hines KL, Kulkarni AB, McCarthy JB, et al. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor β1 knockout mice. Proc Natl Acad Sci USA 1994; 91: 5187.
25. Wieder KJ, Hancock WW, Schmidbauer G, et al. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-γ in rat recipients of cardiac allografts. J Immunol 1993; 151: 1158.
26. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379.
27. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1993; 62: 3.
28. Bergeses S, Pelletier R, Vallera D, Wildmer M, Orosz C. Regulation of endothelial VCAM-1 expression in murine cardiac grafts: roles of TNF and IL-4. Am J Pathol 1995; 146: 989.
29. Schmidbauer G, Hancock WW, Wasowska B, Kupiec-Weglinski JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933.
30. Herskovitz A, Mayne AE, Willoughby SB, Kanter K, Ansari AA. Patterns of myocardial cell adhesion molecule expression in human endomyocardial biopsies after cardiac transplantation: induced ICAM-1and VCAM-1 related to implantation and rejection. Am J Pathol 1994; 145: 1082.